Barchart.com
[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.
Menu

Intellia Thera CS (NTLA)

Intellia Thera CS (NTLA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Image of Cathie Wood via Wikimedia Commons
Intellia Therapeutics Stock Is Down Nearly 95% From Its Record Highs but Cathie Wood Keeps Buying Barchart - Tue May 5, 1:05PM CDT

Despite Intellia's severe stock drop from its 2021 peak, Cathie Wood is buying big.

ARKG : 30.48 (+0.33%)
REGN : 714.89 (+0.82%)
NTLA : 14.09 (+2.77%)
ARKK : 79.12 (+1.53%)
Intellia Therapeutics to Participate in Upcoming Investor Conferences GlobeNewswire - Tue May 5, 6:30AM CDT

CAMBRIDGE, Mass., May 05, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing...

NTLA : 14.09 (+2.77%)
Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire - Fri May 1, 3:01PM CDT

CAMBRIDGE, Mass., May 01, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing...

NTLA : 14.09 (+2.77%)
Intellia Therapeutics Announces Pricing of Public Offering of Common Stock GlobeNewswire - Wed Apr 29, 6:00AM CDT

CAMBRIDGE, Mass., April 29, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing...

NTLA : 14.09 (+2.77%)
Intellia Announces Proposed Public Offering of Common Stock GlobeNewswire - Mon Apr 27, 3:01PM CDT

CAMBRIDGE, Mass., April 27, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing...

NTLA : 14.09 (+2.77%)
Medical research and development by Gorodenkoff via Shutterstock
Intellia Therapeutics Pops on CRISPR Trial Success. Does That Make NTLA Stock a Buy? Barchart - Mon Apr 27, 1:49PM CDT

Intellia Therapeutics stock soars on promising Phase 3 results for its hereditary angioedema (HAE) candidate. But is there any further upside left in NTLA shares?

REGN : 714.89 (+0.82%)
NTLA : 14.09 (+2.77%)
MarketBeat.com
3 Biotech Stocks That Could Benefit from the Patent Cliff MarketBeat - Mon Apr 27, 6:05AM CDT

Biotech M&A is surging ahead of a $300B patent cliff. Here are 3 gene-editing stocks investors are watching as potential acquisition targets

BEAM : 32.32 (+2.70%)
CRSP : 54.83 (+4.60%)
MRK : 111.38 (-0.82%)
BMY : 56.16 (-0.16%)
NTLA : 14.09 (+2.77%)
Intellia Therapeutics Initiates Rolling Submission of Biologics License Application to FDA for Lonvoguran Ziclumeran (lonvo-z) as a One-Time Treatment for Hereditary Angioedema GlobeNewswire - Mon Apr 27, 6:00AM CDT

CAMBRIDGE, Mass., April 27, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing...

NTLA : 14.09 (+2.77%)
Intellia Therapeutics Reports Positive Phase 3 Results in Hereditary Angioedema, Marking a Global First for In Vivo Gene Editing GlobeNewswire - Mon Apr 27, 6:00AM CDT

Phase 3 HAELO trial of lonvoguran ziclumeran (lonvo-z) met primary and all key secondary endpoints;  favorable safety and tolerability data observed Single dose of lonvo-z freed most patients from...

NTLA : 14.09 (+2.77%)
Intellia Therapeutics to Report Topline Data from Global Phase 3 HAELO Clinical Trial of Lonvoguran Ziclumeran in Hereditary Angioedema on April 27, 2026 GlobeNewswire - Fri Apr 24, 3:05PM CDT

World’s first Phase 3 readout for an  in vivo CRISPR gene editing candidate Company to host webcast to discuss data at 8:00 a.m. ET on April 27, 2026 CAMBRIDGE, Mass., April 24, 2026 (GLOBE...

NTLA : 14.09 (+2.77%)

Barchart Exclusives

Palantir Stock Has a ‘High-Class Problem’: Demand for Its Software Is Far Outpacing Supply Barchart - Sun May 10, 4:00PM CDT
Palantir’s greatest challenge may no longer be demand, but how quickly it can deliver AI software to customers. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.